Creatine and Cancer: What the Research Actually Shows

In 2019, a lab at UCLA published a paper showing that killer T cells, the immune cells that hunt down tumors, depend on creatine to do their job. Two years later, a different lab published a paper showing that creatine helped tumors spread in mice. Both papers are real, both appeared in serious journals, and both are still standing.

That contradiction is the honest starting point for anyone searching for information on creatine and cancer. So here is the short answer up front. The research connecting creatine to cancer, in either direction, is almost entirely preclinical, meaning it comes from mice and cells rather than people. Some mouse studies found that creatine strengthened immune attacks on tumors. At least one prominent mouse study found the opposite, that creatine fueled metastasis. The human trials that exist looked at muscle and weight in people who already had cancer, and most of them found no effect at all. Nobody has run a trial testing whether creatine changes cancer outcomes in humans, and until someone does, every strong claim you read on this topic, hopeful or scary, is running ahead of the evidence.

This article walks through what the studies actually found, in whom, at what doses, and why the field is genuinely split. It is a longer read than most creatine content, because this topic does not survive being compressed into a headline.

What the Evidence Actually Shows

Before going deep, here is the map of the territory as of late 2026.

First, there is a body of preclinical work suggesting creatine supports antitumor immunity. The anchor study is the 2019 Journal of Experimental Medicine paper from Lili Yang’s group at UCLA, which found that CD8 T cells infiltrating mouse tumors sharply increased expression of the creatine transporter gene, that mice unable to take up creatine controlled tumors poorly, and that creatine supplementation slowed tumor growth in several mouse models. A 2023 study extended the idea to macrophages, another immune cell type. This work is elegant and has held up to scrutiny so far.

Second, there is a body of preclinical work suggesting the opposite. A 2021 Cell Metabolism paper reported that creatine promoted metastasis of colorectal and breast cancer in orthotopic mouse models and shortened the animals’ survival. Other groups have reported that creatine kinase, the enzyme that puts creatine to work, is overexpressed in many tumors and can support cancer cell energy demands.

Third, there is a small set of human trials. They did not test tumor outcomes. They tested whether creatine helps people with cancer preserve muscle, strength, or weight. The largest was a 263 person randomized trial in cancer related weight loss, and it found nothing. Two recent smaller trials, one in breast cancer survivors and one in men with prostate cancer on hormone therapy, also found no added benefit over exercise or placebo.

Fourth, on the separate question of whether taking creatine causes cancer, reviews of the safety literature have consistently found no supporting evidence for that claim in humans.

If you take one thing from this article, take the shape of that map: promising mouse immunology, a genuine red flag from a different mouse model, null human trials on supportive outcomes, and no human data at all on the question everyone actually wants answered.

The Discovery That Started the Hype: T Cells Run on Creatine

The reason creatine shows up in cancer research at all comes down to energy. A CD8 T cell attacking a tumor is one of the hungriest cells in the body, and the tumor microenvironment, the immediate neighborhood around a tumor, is a nutrient desert. Cancer cells are notorious for hogging glucose and other fuels. Immune cells that enter that environment often run out of gas, a state researchers call T cell exhaustion.

Creatine’s whole job in physiology is energy buffering. Cells store it as phosphocreatine, a charged form that can regenerate ATP, the cell’s energy currency, almost instantly when demand spikes. Muscle uses this system. So does the brain. The question the UCLA team asked was whether tumor fighting immune cells use it too.

Their answer, published as Di Biase and colleagues in the Journal of Experimental Medicine in 2019, was yes, and emphatically. When they profiled immune cells inside mouse melanoma tumors, expression of the creatine transporter gene, called Slc6a8 or CrT, shot up compared with immune cells in the spleen. The transporter is the doorway that lets creatine into a cell, so upregulating it is a cell’s way of asking for more. Strikingly, the most exhausted T cells, the ones wearing the most markers of burnout, expressed the most transporter, as though they were reaching hardest for extra energy.

The team then ran the experiment in both directions. Mice genetically unable to take up creatine mounted weak antitumor T cell responses and controlled tumors poorly. Wild type mice given supplemental creatine, either orally or by injection, showed suppressed tumor growth across multiple mouse tumor models. And when the researchers combined creatine with PD-1 blockade, a class of immunotherapy that releases the brakes on T cells, the combination suppressed tumors more than either intervention alone.

A follow up study from a Japanese group, published in 2023 and available through PubMed Central, found a second mechanism. In mice with B16 melanoma, creatine supplementation pushed tumor associated macrophages toward an inflammatory, tumor fighting profile, boosted their ATP production through the phosphocreatine system, and increased the number of tumor specific CD8 T cells downstream. Blocking the creatine transporter erased all of it, including the tumor suppression.

This is genuinely interesting biology. It is also, and this matters, biology observed in mice, at supplementation levels designed for mouse experiments, in transplanted tumor models that only partially resemble human cancer. The researchers themselves framed the work as a rationale for clinical trials, not as a recommendation. Seven years later, those trials still have not happened.

The Study the Supplement Industry Prefers to Forget

In April 2021, a team led by Pengcheng Bu at the Chinese Academy of Sciences published a paper in Cell Metabolism with a title that could not be clearer: Creatine promotes cancer metastasis through activation of Smad2/3.

Using orthotopic mouse models, which means tumors implanted in the organ where that cancer naturally arises rather than under the skin, the group found that dietary creatine enhanced the spread of colorectal and breast cancer to the liver and shortened the animals’ survival. They traced a mechanism, too. Creatine activated proteins called Smad2 and Smad3 through an enzyme called MPS1, which switched on Snail and Slug, two genes with a well documented role in helping cancer cells detach and invade. The team also found that GATM, the rate limiting enzyme for the body’s own creatine synthesis, was upregulated in liver metastases, and that knocking it down suppressed spread and extended survival.

The authors explicitly warned that cancer patients should be cautious about creatine supplements. A commentary in the same journal amplified the message.

Here is my honest read after sitting with this paper and the responses to it for a while. It is a serious piece of work from a credible group, published in a top metabolism journal, and it should not be waved away. At the same time, it has a specific and important limitation that later reviewers have flagged. As a 2026 systematic review in Cureus pointed out, key metastasis experiments were run in severely immunocompromised mice. That detail is not a technicality. If creatine’s main anticancer effect in other studies runs through immune cells, then a mouse without a functioning immune system removes the benefit side of the ledger entirely and can only reveal the harm side. In an animal with an intact immune system, the two effects would compete, and nobody yet knows which one wins.

So the field is left with a genuinely unresolved tension. Creatine appears to energize both the attackers and, at least in some models, the tumor cells themselves. Reviews with titles like The Two Sides of Creatine in Cancer, indexed on PubMed in 2021, exist because the literature really does point both ways.

How Researchers Are Trying to Reconcile the Split

The 2026 Cureus systematic review is the most useful attempt so far to put the pieces together. The authors screened 230 articles and found only five studies that met their criteria for examining creatine alongside immune checkpoint inhibitor therapy, all of them preclinical. Their conclusion, roughly paraphrased, was that creatine plus PD-1 blockade looks beneficial in immunocompetent mouse models, largely through improved T cell energy metabolism and macrophage activity, while the metastasis findings in other tumor models remain a live concern, and that the total absence of human data is the defining feature of the field.

That framing matches what you see when you line the studies up. The tumor suppression results come from models with working immune systems. The metastasis result comes primarily from a model where the immune contribution was absent or crippled. Context appears to be everything: the tumor type, the creatine kinase activity of the specific cancer, the state of the host’s immune system, and the presence or absence of immunotherapy.

There is even older work that complicates the picture further in an unexpected direction. Back in the 1990s, researchers found that cyclocreatine, a synthetic creatine analog, inhibited the growth of a broad range of tumor cell lines, and a 2000 study in nude mice found that dietary creatine itself at high concentrations slowed the growth of human colon adenocarcinoma xenografts. More recently, a 2022 Cancer Research paper reported that prostate tumors in mice ramp up creatine uptake and that cyclocreatine treatment impaired their progression, which frames the creatine pathway as a drug target rather than creatine as a helpful supplement. A field where the same molecule’s pathway can be both a proposed therapy and a proposed drug target is a field that has not sorted itself out yet.

I want to be plain about what this means for a reader. Anyone who tells you creatine fights cancer is overselling mouse immunology. Anyone who tells you creatine spreads cancer is overselling a different set of mouse experiments. The correct summary is that the biology is real, bidirectional, and unresolved, and that human outcome data does not exist.

What Happened When Creatine Met Actual Patients

Creatine has been given to people with cancer in randomized trials. Not to treat the disease, but to address something adjacent: the loss of muscle, strength, and weight that cancer and its treatments cause. These trials are worth knowing about, partly for their own sake and partly because they are a sobering lesson in how findings that look solid in healthy populations can evaporate in sick ones.

The biggest is the N02C4 Alliance trial, a double blind, placebo controlled randomized study published in Annals of Oncology in 2017. Researchers led by Aminah Jatoi enrolled 263 patients with cancer related anorexia and weight loss and gave half of them creatine, using a loading dose followed by daily maintenance, and half placebo. The result was as null as results get. Over the first month, exactly three patients gained ten percent or more of baseline weight, two on creatine and one on placebo. Appetite, quality of life, and survival did not differ. Median survival was 230 days with creatine and 239 with placebo. The authors reported that no trend ever emerged suggesting the supplement was doing anything.

More recent and smaller trials point the same way. A 2024 study by Parsowith and colleagues in Nutrients gave 19 female breast cancer survivors, average age about 58, either creatine at 5 grams four times daily for a week or a dextrose placebo, then tested sit to stand power, isometric and isokinetic torque, and upper and lower body strength. The trial found no significant supplement by time interaction on any performance measure, though it was short and small, which the authors acknowledged.

Then there is the trial I think deserves the most attention, because it was well designed and squarely negative. Fairman and colleagues randomized 30 men with prostate cancer undergoing androgen deprivation therapy, a treatment that suppresses testosterone and strips away muscle, to twelve weeks of supervised resistance training plus either creatine or placebo. The paper, published in the Journal of Science and Medicine in Sport in 2025, is titled bluntly: creatine supplementation does not add to resistance training effects in prostate cancer patients under androgen deprivation therapy. Exercise helped. Creatine added nothing measurable on lean mass, strength, or physical function.

The mouse work on this question, interestingly, is more encouraging than the human work, which is the reverse of how these stories usually go. A 2022 study in Frontiers in Pharmacology reported that people with cancer cachexia, the severe wasting syndrome that accompanies advanced disease, had significantly lower serum creatine than patients without cachexia, and that creatine supplementation in C26 tumor bearing mice partially protected against weight loss and muscle breakdown by damping the protein degradation pathways that cachexia switches on. It is a mechanistically tidy result. It is also exactly the kind of result the N02C4 trial was positioned to confirm in humans five years earlier and did not, which is a useful reminder that a clean mouse mechanism guarantees nothing about a clinical outcome.

Why would a supplement with hundreds of positive strength studies in healthy and older adults go quiet in cancer populations? Nobody knows for certain. Hormone suppression, systemic inflammation, altered muscle biology, small samples, and short durations are all candidate explanations. Larger trials are underway, including the THRIVE study in breast cancer survivors, which uses a 20 grams per day loading week followed by 5 grams daily alongside twelve weeks of exercise, and the Spanish CaRTiC trial pairing 5 grams daily with sixteen weeks of resistance training. Until those report, the honest statement is that creatine’s supportive benefits in people with cancer are unproven, and the trials run so far mostly found nothing.

One more note on this section, because it matters for how you read everything else. These null results do not tell us anything about tumor growth or spread, in either direction. None of these trials was designed to detect effects on the cancer itself, and none reported safety signals suggesting harm. They measured muscle, and the muscle did not respond.

Does Taking Creatine Cause Cancer

This is the other question people type into search engines, and it deserves a direct answer rather than a shrug.

The worry has two sources. The first is heterocyclic amines, compounds that form when creatine, amino acids, and sugars react at high cooking temperatures, and which are associated with cancer risk in the context of heavily charred meat. The second is the general observation, discussed above, that creatine metabolism can support the energy needs of some cancer cells.

On the first point, a 2025 review in Frontiers in Nutrition examining the most common creatine safety concerns concluded that the available research does not support a link between creatine supplementation and cancer in humans. Supplemental creatine is not cooked at high heat inside your body, and the amounts of heterocyclic amines relevant to risk come from charring meat, not from swallowing creatine monohydrate. The review’s more practical warning was about product purity, since poorly manufactured supplements can carry contaminants, which is an argument for choosing products with verified quality testing, not an argument against the molecule.

On the second point, the concern is theoretical for a person without cancer and unquantified for a person with it. Memorial Sloan Kettering Cancer Center, whose integrative medicine database maintains a regularly updated professional monograph on creatine, summarizes both the immune findings and the metastasis findings and does not conclude that creatine causes cancer. Oncology professional resources generally land in the same place: no established causal link, combined with a recommendation that patients with active cancer discuss any supplement with their oncology team, particularly given creatine’s effect on creatinine levels, which can complicate the interpretation of kidney function tests during treatment.

That last recommendation is not boilerplate. If there is one group for whom the uncertainty in this literature is a live, practical issue, it is people currently undergoing cancer treatment. The mouse data cuts both ways, drug interactions and lab test interference are real considerations, and an oncologist who knows the specific cancer type is the only person positioned to weigh any of it. A blog, this one included, cannot do that job.

Who These Findings Apply To and Who They Do Not

Research this early gets misapplied constantly, so it is worth spelling out the boundaries. I have watched the same three studies get quoted in fitness forums, cancer support groups, and supplement marketing over the past few years, each audience taking the half of the literature it prefers, and the misreadings follow a predictable pattern.

The immune findings apply to mice with transplanted tumors, often receiving creatine at doses and by routes chosen for experimental effect, sometimes by injection into the abdomen. They do not establish anything about a healthy adult taking 5 grams of creatine monohydrate daily, and they establish even less about preventing cancer, a question no study in this entire literature has addressed.

The metastasis findings apply to specific orthotopic mouse models of colorectal and breast cancer, with the immunocompromised host caveat already discussed. They do not establish that creatine supplementation spreads cancer in humans, and epidemiological evidence connecting creatine use to worse cancer outcomes in people does not currently exist.

The null supportive care trials apply to the populations studied: patients with advanced cancer and weight loss, breast cancer survivors shortly after treatment, and men on androgen deprivation therapy. They do not overturn the large evidence base for creatine and muscle performance in healthy adults, and they do not apply to cognition, which is the territory this site usually covers and which involves an entirely separate literature.

And none of this research says anything about any particular creatine product. These studies used plain creatine monohydrate or laboratory creatine. No formulation, drink, or delivery format has been tested in any cancer context, full stop.

If you are healthy and take creatine for training or for the modest cognitive findings in specific situations, the current human safety literature, including the 2025 Frontiers review, gives no reason to believe you are raising your cancer risk. If you have cancer now or are in active treatment, do not make this decision from articles on the internet. Bring it to your oncologist, mention the Cell Metabolism findings if you want a concrete reference, and let someone who knows your case weigh in.

What Would Change the Picture

Because this field is young, it is unusually easy to say what would move it forward, and I would genuinely like to see all of it happen.

A phase one trial of creatine alongside checkpoint inhibitor therapy would be the single most informative step. The preclinical synergy with PD-1 blockade is the most exciting finding in this literature, and it is testable: the 2026 systematic review authors called early phase trials essential, and the safety profile of creatine in healthy populations makes such a trial plausible to design. If that synergy appeared in humans, this topic would stop being a curiosity. If it did not, that would matter just as much, and this site would report it either way.

Resolution of the metastasis question in immunocompetent models would be nearly as valuable. Someone needs to run the orthotopic spread experiments in mice with intact immune systems, head to head, with and without supplemental creatine. Until that happens, the two halves of the mouse literature cannot really be compared.

Results from THRIVE, CaRTiC, and the other ongoing exercise plus creatine trials in survivors will settle whether the supportive care nulls reflect underpowered studies or a real biological difference in how muscle responds to creatine after cancer treatment.

And long term observational data on creatine users and cancer incidence, imperfect as observational data always is, would at least put boundaries on the risk question that mouse models can never answer.

The state of creatine and cancer research in 2026 is, in a strange way, a good test of whether a source deserves your trust. The evidence is split enough that anyone can cherry pick a study to support whatever they were already selling, fear or hope. The papers themselves, read together, support neither. They support curiosity, caution for people in active treatment, and patience while the human trials that should have started years ago finally get run.